期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

氟达拉滨治疗慢性淋巴细胞白血病41例临床观察 被引量：2

原文传递
导出
摘要 本研究中我们对以CD38、ZAP-70和遗传学异常（11q-、17p-）筛选出的高危慢性淋巴细胞白血病（CLL）患者，进行早期氟达拉滨单药，以及氟达拉滨为主方案的干预治疗，对已有治疗指征的CLL患者，观察应用此方案的治疗效果及其与临床相关指标的关系。
作者 徐卫 李建勇 吴汉新 钱思轩 陆化 仇红霞 曹祥山 李丽 于慧 盛瑞兰
机构地区 南京医科大学第一附属医院、江苏省人民医院血液科 常州市第一人民医院血液科
出处 《中华血液学杂志》 CAS CSCD 北大核心 2008年第1期54-56,共3页 Chinese Journal of Hematology
基金 江苏省医学领军人才项目 江苏省“兴卫”工程重点人才项目（RC2007042） 江苏省自然科学基金（BK2007249） 江苏省社会发展计划（BS2007075）
关键词 慢性淋巴细胞白血病 氟达拉滨 干预治疗 临床观察 ZAP-70 临床相关指标 遗传学异常 CD38
分类号 R686 [医药卫生—骨科学]
  • 相关文献

参考文献9

  • 1Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer, 1981, 48:198-206.
  • 2徐卫,李建勇,潘金兰,仇海荣,沈云锋,肖冰,陈丽娟,吴亚芳,盛瑞兰,薛永权.慢性淋巴细胞白血病的分子遗传学特点[J].中华肿瘤杂志,2006,28(5):349-352. 被引量：13
  • 3Grever MR, Kopecky KJ, Coltman CA, et al. Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol, 1988, 30: 457-459.
  • 4Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood, 1989, 74 : 19-25.
  • 5Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med, 2000, 343:1750-1757.
  • 6O' Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol, 2001, 19 : 1414-1420.
  • 7Keating M J, O' Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol, 2005, 23:4079-4088.
  • 8Stilgenbauer S, Dohner H. Molecular genetics and its clinical relevance. Hematol Oncol Clin North Am, 2004, 18:827-848.
  • 9Keating M J, Smith TL, Lerner S, et al. Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia. Leuk Lymphoma, 2000, 37: 71-85.

二级参考文献10

  • 1张颜明.荧光原位杂交技术检测外周T细胞淋巴瘤的染色体畸变[J].中华肿瘤杂志,1995,17(3):187-190. 被引量：5
  • 2Glassman AB,Hayes KJ.The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia.Cancer Genet Cytogenet,2005,158:88-91.
  • 3International Workshop on Chronic Lymphocytic Leukemia.Chronic lymphocytic leukemia:recommendations for diagnosis,staging,and response criteria.Ann Intern Med,1989,110:236-238.
  • 4Stilgenbauer S,Dohner K,Bentz M,et al.Molecular cytogenetic analysis of B-cell chronic lymphocytic leukemia.Ann Hematol,1998,76:101-110.
  • 5Dewald GW,Brockman SR,Paternoster SF,et al.Chromosome anomalies detected by interphase fluorescence in situ hybridization:correlation with significant biological features of B-cell chronic lymphocytic leukaemia.Br J Haematol,2003,121:287-295.
  • 6Aoun P,Blair HE,Smith LM,et al.Fluorescence in situ hybridization detection of cytogenetic abnormalities in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma.Leuk Lymphoma,2004,45:1595-1603.
  • 7Thornton PD,Gruszka-Westwood AM,Hamoudi RA,et al.Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia.Hematol J,2004,5:47-54.
  • 8夏建川,肖晟,张建华,刘权章,张贵寅,李璞.28例原发性胃癌的直接染色体分析和荧光原位杂交检测[J].中华肿瘤杂志,1999,21(5):345-349. 被引量：8
  • 9李建勇,潘金兰,薛永权,吴春华,谢新,过宇,阮长耿.间期荧光原位杂交检测骨髓增生异常综合征8号染色体三体[J].中华血液学杂志,2000,21(4):179-181. 被引量：24
  • 10李建勇,潘金兰,吴亚芳,过宇,薛永权.间期荧光原位杂交技术检测急性粒-单核细胞白血病inv(16)[J].中华血液学杂志,2002,23(1):30-32. 被引量：24

共引文献12

同被引文献13

  • 1田怀平,卜书红,李方.氟达拉宾的药物学及应用[J].北京医学,2004,26(5):351-353. 被引量：4
  • 2陈艳,乌学真,符仁义,廖清奎.IDA-FLAG方案治疗小儿难治性、复发性急性白血病的临床观察[J].临床儿科杂志,2005,23(10):740-742. 被引量：4
  • 3顾龙君.儿童急性淋巴细胞白血病诊疗建议(第三次修订草案)[J].中华儿科杂志,2006,44(5):392-395. 被引量：483
  • 4Hainsworth JD, Vazquez ER, Spigel DR, et ol. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network [ J ]. Cancer, 2008,112 (6) : 1288 - 195.
  • 5Ferrara F, Leoni F, Pinto A, et ol. Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromes [J]. Cancer, 1999,86(10) :2006-2013.
  • 6Nguyen K, Devidas M, Cheng SC, et ol. Factors influencing survival after relapse from acute lymphoblastic leukemia : a Children's Oncology Group study [ J ]. Leukemia, 2008,22(12) :2142-2150.
  • 7World Health Organization. Handbook for reporting results of cancer treatment [ M ]. Geneva Switzerland : World Health Organization, 1979 : 15-22.
  • 8Virchis A, Koh M, Rankin P, et ol. Fludarabine, cytosinearabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukemia or myelodysplastic syndromes [Jl. Br J Haematol, 2004,124(1 ) : 26-32.
  • 9Giebel S, Krawczyk-Kulis M, Adamczyk-Cioch M, et al. Fludarabine, cytarabine, and mitoxantrone (FLAM)for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Aduh Leuke-mia Group (PALG) [J]. Ann Hemotol,2006,85(10) : 717-722.
  • 10Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG- 2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group [J]. Blood,2008,111 (3) : 1044- 1053.

引证文献2

二级引证文献6

中华血液学杂志
2008年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部